A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study (MEADOWSPRING)

Roche

Status: Terminated

Conditions: COVID-19; Long COVID

Study type: Observational

Funder types: Industry

Identifiers

NCT05059080

2021-000627-12 (EudraCT Number)

CV43140

Details and patient eligibility

About

This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]), for approximately 6 months after the end of the parent study.

Enrollment: 72 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant was diagnosed with COVID-19 and enrolled in a Phase III RO7496998 (AT-527) COVID-19 study

Exclusion criteria

• Participation in an interventional study at the time of enrollment or plans to enroll in an interventional study during this study.
• Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

Trial design

72 participants in 1 patient group

Participants Diagnosed with COVID-19

Description:

Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 \[CV43043\]).